olorofim: Clinical Trials

5 trials of olorofim, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 withdrawn, 1 completed, 1 not yet recruiting, 1 recruiting. 5 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Withdrawn 2, Completed 1, Not yet recruiting 1, Recruiting 1
Phase 12Withdrawn 2

Follow olorofim: new trials by email Literature Review of olorofim trials Research Report on olorofim

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care
Olorofim, Placebo - Coccidioidomycosis, Disseminated Fungal Infection
Phase 2Not yet recruitingF2G Ltd502026-12-012026-09-22
Olorofim in Early Coccidioidal Meningitis
olorofim - Coccidioidal Meningitis
Phase 2RecruitingFariba Donovan122026-06-012026-07-27
Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
Olorofim - Invasive Fungal Infections
Phase 2CompletedF2G Biotech GmbH2032018-06-062024-07-10
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
F901318, Caspofungin - Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnF2G Ltd2017-04-202018-02-15
Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia
F901318 with fluconazole low dose, F901318 with fluconazole high dose, F901318 with posaconazole - Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnF2G Ltd2017-03-012018-02-15

Conditions studied

Coccidioidomycosis (3)  ·  Invasive Fungal Infections (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Coccidioidal Meningitis (1)  ·  Invasive Pulmonary Aspergillosis (1)  ·  Mycoses (1)

Sponsors

F2G Ltd (3)  ·  F2G Biotech GmbH (1)  ·  Fariba Donovan (1)

Countries

United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Egypt (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)  ·  Thailand (1)  ·  Turkey (Türkiye) (1)

Top investigators

Fariba Donovan, MD, PhD (1)  ·  George R. Thompson, MD (1)  ·  Oliver A Cornely, MD (1)  ·  Oliver Cornely, PhD, MD (1)  ·  Sharon Chen (1)

Results publications

PMID 40541222, PMID 41914555, PMID 42008658, PMID 42475691